𝔖 Bobbio Scriptorium
✦   LIBER   ✦

647 Genetic variants of hepatobiliary transporter and nuclear receptor genes and response to ursodeoxycholic acid in primary biliary cirrhosis

✍ Scribed by V. Barbu; C. Ping; C. Corpechot; Y. Chrétien; E. Matsuda; O. Chazouillières; T. Simon; R.E. Poupon; R. Poupon

Book ID
117374923
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
125 KB
Volume
44
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral budesonide in the treatment of pati
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
✍ Paul Angulo; Roberta A. Jorgensen; Jill C. Keach; E. Rolland Dickson; Coleman Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC). However, some patients show an incomplete response to UDCA therapy. Treatment with corticosteroids may be of benefit although at the expense of systemic side effects. Budesonid

Does antimitochondrial antibody status a
Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation
✍ W R Kim; J J Poterucha; R A Jorgensen; K P Batts; H A Homburger; E R Dickson; R 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

rum. 1 In the past decade, two treatment modalities have Approximately 5% to 10% of patients with features otherbeen shown to be effective in the treatment for PBC, dewise consistent with primary biliary cirrhosis (PBC) lack antipending on the stage of the disease. For patients with less mitochondri